全文获取类型
收费全文 | 103篇 |
免费 | 8篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 2篇 |
基础医学 | 4篇 |
口腔科学 | 5篇 |
临床医学 | 5篇 |
内科学 | 39篇 |
皮肤病学 | 1篇 |
神经病学 | 13篇 |
特种医学 | 6篇 |
外科学 | 14篇 |
预防医学 | 4篇 |
药学 | 9篇 |
中国医学 | 1篇 |
肿瘤学 | 9篇 |
出版年
2024年 | 2篇 |
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 11篇 |
2020年 | 6篇 |
2019年 | 9篇 |
2018年 | 4篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 3篇 |
2014年 | 2篇 |
2013年 | 7篇 |
2012年 | 6篇 |
2011年 | 10篇 |
2010年 | 2篇 |
2009年 | 10篇 |
2008年 | 8篇 |
2007年 | 7篇 |
2006年 | 10篇 |
2005年 | 4篇 |
2004年 | 2篇 |
2002年 | 1篇 |
排序方式: 共有113条查询结果,搜索用时 46 毫秒
41.
Papathanasiou ND Rondogianni PE Pianou NK Karampina PA Vlontzou EA Datseris IE 《Nuclear medicine communications》2008,29(3):239-246
BACKGROUND AND AIM: (99m)Tc-depreotide is a (99m)Tc-labelled somatostatin analogue, with high affinity for the 2, 3 and 5 subtypes of somatostatin receptors. These particular receptors are over-expressed on the surface of activated leucocytes, which mediate inflammatory response. Based on this property this study tried to investigate whether (99m)Tc-depreotide scintigraphy could be a useful complementary method in the investigation of bone infection and inflammation. METHODS: Twenty-three patients, who were investigated for probable osteomyelitis, underwent three-phase bone scintigraphy followed by (99m)Tc-depreotide scintigraphy. Clinical and laboratory findings, complementary imaging procedures, clinical follow-up and bone biopsy established the final diagnosis. (99m)Tc-depreotide scintigraphy was performed 3 h after the intravenous administration of 555-740 MBq of the radiopharmaceutical. Scintigraphic images were, at first, blindly interpreted alone and then in comparative assessment with bone scans. RESULTS: (99m)Tc-depreotide was positive in 12/12 cases of active osteomyelitis, one case of recent femoral head osteonecrosis and 6/9 rheumatoid arthritis sites. Negative (99m)Tc-depreotide scans were acquired in five cases of 'no-inflammation' (an uncomplicated fracture, an aseptic loosening of prosthesis, an old osteonecrosis, a healed and a successfully treated osteomyelitis), as well as in 14/14 total sites of degenerative arthritis-osteoarthropathy. In five cases (septic arthritis, periodontal and soft tissue infections) (99m)Tc-depreotide was positive, though spatially discordant with bone scintigraphy, delineating precisely the focus of infection. CONCLUSION: (99m)Tc-depreotide can be a useful complementary imaging method in the evaluation of bone infection and inflammation. Its combination with three-phase bone scintigraphy seems to be accurate in localizing the infection foci and determining the activity of the inflammatory processes. 相似文献
42.
Prevalence and patterns of permanent tooth agenesis in individuals with Down syndrome: a meta‐analysis 下载免费PDF全文
The aims of the present study were to evaluate the prevalence and patterns of permanent tooth agenesis in individuals with Down syndrome, using meta‐analysis methodology. Two independent investigators carried out a literature search to locate articles pertaining to permanent tooth agenesis in individuals with Down syndrome. The outcomes of interest were the prevalence and pattern of permanent tooth agenesis. Thirteen articles were selected for inclusion. The estimated overall prevalence of permanent tooth agenesis, excluding third molars, was 54.6% (95% CI: 44–66%). Considerable heterogeneity was present across the studies. Among subjects with tooth agenesis, approximately half had three or more missing teeth. The permanent teeth with the highest prevalence of agenesis were the maxillary lateral incisor (27%), mandibular second premolar (21%) and maxillary second premolar (18%). The single most commonly absent tooth, however, was the mandibular left second mandibular premolar (19.9%), followed by the maxillary left lateral incisor (19.4%). Little data describing specific tooth‐agenesis patterns were available. In conclusion, individuals with Down syndrome display high prevalence rates and severity of agenesis of permanent teeth. Proper and timely diagnosis of missing permanent teeth is thus necessary, to allow a more comprehensive long‐term treatment plan and a more favorable prognosis in these individuals. 相似文献
43.
44.
Pinelopi Samara Kyriaki Ioannou Monica Neagu Niki Arnogiannaki Alexandros Ardavanis Wolfgang Voelter Ourania Tsitsilonis 《International immunopharmacology》2013,15(1):50-57
Neutrophils are short-lived leukocytes and major components of the innate immune system. They are key players in the body's defense against pathogens, but their contribution to tumor growth and metastasis is controversial. Nevertheless, improving the functions of neutrophils in cancer patients, particularly in those undergoing chemotherapy, is of clinical significance. In this study, we investigated the ability of the immunoreactive fragment of the polypeptide prothymosin alpha (proTα), i.e., the decapeptide proTα(100–109), to enhance the functions of neutrophils isolated from the peripheral blood of breast cancer patients in comparison with those from healthy donors. Activation of neutrophils from both groups with proTα(100–109) significantly increased phagocytosis and the production of intracellular reactive oxygen species (ROS) compared to controls. The release of extracellular ROS and oxidative burst of proTα(100–109)-stimulated neutrophils were less improved. Most importantly, upon activation with proTα(100–109), neutrophils from breast cancer patients showed significantly enhanced cytotoxicity against tumor cell targets. Using a scrambled peptide as a control, we showed that the proTα(100–109)-induced effects were sequence-specific and comparable to those exerted by the parental molecule proTα. The responsiveness of neutrophils to proTα(100–109) or intact proTα did not correlate with the tumor grade or other established tumor characteristics. Our results suggest that proTα(100–109) activates neutrophils, particularly those derived from breast cancer patients, and these effects could potentially be used to improve some functions of neutrophils in the clinical setting. 相似文献
45.
46.
47.
Tsochatzis EA Manousou P Fede G Dhillon AP Burroughs AK 《Gut》2011,60(10):1442-3; author reply 1443-4
48.
Pinelopi Manousou George Kalambokis Federica Grillo Jennifer Watkins Elias Xirouchakis Maria Pleguezuelo Gioacchino Leandro Vasiliki Arvaniti Giacomo Germani David Patch Vincenza Calvaruso Dimitri P. Mikhailidis Amar P. Dhillon Andrew K. Burroughs 《Liver international》2011,31(5):730-739
Introduction: Differentiation between steatosis and non‐alcoholic steatohepatitis (NASH) in non‐alcoholic fatty liver disease (NAFLD) is important as NASH progress to cirrhosis. No specific laboratory/imaging technique exists either to diagnose NASH or to select patients for liver biopsy. Patients and methods: We evaluated serum ferritin and the features of metabolic syndrome with respect to histological inflammation and/or fibrosis in NAFLD patients. The Kleiner scoring system was used to classify NAFLD in consecutive liver biopsies. One hundred and eleven patients: median age 52.6, 64 males, obesity 62, diabetes mellitus (DM) 58, arterial hypertension 26 and hyperlipidaemia 40%. Results: Histologically, 40.7 had fatty liver, 30.6% had borderline NASH, 28.7% had NASH and 11% had cirrhosis. Multivariate regression showed that diabetes, serum ferritin concentrations, body mass index (BMI) and AST were independently associated with NASH: together, the areas under the receiver operating characteristic (AUROC) was 0.91 (95% confidence interval 0.86–0.96); fibrosis was associated with ferritin concentrations and BMI: AUROC 0.87, portal inflammation with ferritin and DM: AUROC 0.82, while lobular inflammation was associated with BMI, DM and ferritin: AUROC 0.85. Conclusion: Serum ferritin concentrations and BMI are strongly associated with fibrosis, portal and lobular inflammation in NAFLD patients. Both ferritin and BMI are potential discriminant markers to select patients for liver biopsy and are associated with inflammation and fibrosis. 相似文献
49.
Edward S. Chambers PhD Claire S. Byrne PhD Annette Rugyendo RD Douglas J. Morrison PhD Tom Preston PhD Catriona Tedford PhD Jimmy D. Bell PhD Louise Thomas PhD Arne N. Akbar PhD Natalie E. Riddell PhD Rohini Sharma MBBS Mark R. Thursz MD Pinelopi Manousou MD Gary Frost PhD 《Diabetes, obesity & metabolism》2019,21(2):372-376
The short chain fatty acid (SCFA) propionate, produced through fermentation of dietary fibre by the gut microbiota, has been shown to alter hepatic metabolic processes that reduce lipid storage. We aimed to investigate the impact of raising colonic propionate production on hepatic steatosis in adults with non-alcoholic fatty liver disease (NAFLD). Eighteen adults were randomized to receive 20 g/d of an inulin-propionate ester (IPE), designed to deliver propionate to the colon, or an inulin control for 42 days in a parallel design. The change in intrahepatocellular lipid (IHCL) following the supplementation period was not different between the groups (P = 0.082), however, IHCL significantly increased within the inulin-control group (20.9% ± 2.9% to 26.8% ± 3.9%; P = 0.012; n = 9), which was not observed within the IPE group (22.6% ± 6.9% to 23.5% ± 6.8%; P = 0.635; n = 9). The predominant SCFA from colonic fermentation of inulin is acetate, which, in a background of NAFLD and a hepatic metabolic profile that promotes fat accretion, may provide surplus lipogenic substrate to the liver. The increased colonic delivery of propionate from IPE appears to attenuate this acetate-mediated increase in IHCL. 相似文献
50.
Dr. Elpis Hatziagorou Mrs. Eleana Kouroukli Mrs. Maria Galogavrou Mrs. Dafni Papanikolaou Dr. Despoina Terzi Dr. Pinelopi Anagnostopoulou 《The Journal of asthma》2019,56(6):573-580
Background: Inhaled Corticosteroids (ICS) are the cornerstone of asthma management in pediatric patients. However, in some cases, asthma is not adequately controlled on ICS alone. Long-acting beta2-agonists (LABA) are one of the available additional therapies but their use has rarely been studied among children younger than 5 years. Objective: The aim of this observational study was to evaluate the efficacy and safety of the combination of fluticasone propionate and salmeterol (FP/SA) in asthmatic children younger than 5 years of age. Methods: A retrospective study of 796 children under the age of 5 years (2.87 ± 1.22 years, 64.2% males), who were treated with FP/SA was conducted. Hospitalization rates, frequency of wheezing, exercise induced asthma, nocturnal wheeze and drug-related side-effects were recorded through children's medical records. Results: The children had previously received short-acting β2-agonists (73%), ICS (17%), montelukast (1%), and ICS with montelukast (2%). Mean duration of therapy with FP/SA was 12.45 ± 9.14 months. After adjusting for age, gender, and duration of treatment, a 89% reduction was recorded in annual hospitalization rates (from 27.13% before treatment to 3.01% after FP/SA therapy, p < 0.001), a 71% reduction in incidence of exercise-induced asthma (36.8% vs. after 10.6%, p < 0.001), a 81% reduction in nocturnal asthma (33.7% vs. after: 6.4%, p < 0.001), as well as in frequency of wheezing (p < 0.01),. No previous treatment carry-on effect was observed. No major drug-related side-effects occurred in the study group. Conclusions: Combination therapy (FP/SA) is well-tolerated and highly effective in asthmatic children under the age of 5 years. 相似文献